Get started
Author

Gabriela Gatica

Institution: Hospital Alemán
ORCID: 0009-0006-4677-5428
Observed ORCID: 0009-0006-4677-5428
OpenAlex ID: A5029854089
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
2021 · Thomas Powles, Tibor Csőszi, et al. · The Lancet Oncology · 660
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
2023 · Kim N. Chi, Dana Rathkopf, et al. · Journal of Clinical Oncology · 381
Treatment Trends in Metastatic Renal Clear Cell Carcinoma in Argentina
2025 · Federico Cayol, Gabriela Gatica, et al. · JCO Global Oncology · 1
[Bone pseudoprogression due to renal neoplasia during treatment with immune checkpoint inhibitors].
2022 · Darío A Rueda, Ailén Martiarena, et al. · PubMed · 1
Retrospective analysis of patients with locally advanced or metastatic urothelial carcinoma treated in Argentina (2018–2025): results from the GUIA 2 study in real-world clinical practice
2026 · Pablo Companys, Tomas Soule, et al. · ecancermedicalscience
PDF
A phase II trial of intravesical gemcitabine/docetaxel plus systemic pembrolizumab in high-risk non–muscle invasive bladder cancer unresponsive to BCG.
2026 · Martin Angel, Federico Losco, et al. · Journal of Clinical Oncology
PDF
Evaluación del tratamiento de primera línea en el carcinoma renal células claras en la Argentina
2025 · Federico Cayol, Gabriela Gatica, et al. · Oncología Clínica
PDF
Causes of discontinuation of intraperitoneal chemotherapy in patients with ovarian cancer.
2012 · Mercedes Tamburelli, Gabriela Gatica, et al. · Journal of Clinical Oncology
Experiencia del instituto angel roffo sobre 125 pacientes neutropenicos febriles
1996 · Valeria Caseres, Lucila Espinoza, et al.
Works count: 9
Citation count: 1,043
H-index: 2
I10-index: 2
Year
Topic
Type